Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

12.5%

1 terminated/withdrawn out of 8 trials

Success Rate

87.5%

+1.0% vs industry average

Late-Stage Pipeline

13%

1 trials in Phase 3/4

Results Transparency

0 of 7 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 1

5(62.5%)

Phase 2

2(25.0%)

Phase 3

1(12.5%)

8Total

Phase 1(5)

Phase 2(2)

Phase 3(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (8)

Showing 8 of 8 trials

NCT00072228Phase 1Withdrawn

Soblidotin and Gemcitabine in Treating Patients With Locally Advanced or Metastatic Solid Tumors

Role: lead

NCT00005091Phase 2Completed

DX-8951f in Treating Previously Untreated Patients With Stage IIIB or Stage IV Non-small Cell Lung Cancer

Role: lead

NCT00325390Phase 3Completed

Efficacy and Safety in Patients With Acute Coronary Syndrome Without ST-Segment Elevation

Role: collaborator

NCT00221091Phase 2Completed

Study to Evaluate Efficacy of Shunt Operation for Idiopathic Normal Pressure Hydrocephalus

Role: collaborator

NCT00002136Phase 1Completed

A Phase I Trial of Tecogalan Sodium (DS-4152) Administered as an Infusion Every 21 Days

Role: lead

NCT00002138Phase 1Completed

A Phase I Trial of Tecogalan Sodium ( DS-4152 ) Administered as an Infusion Twice Weekly for 21 Days.

Role: lead

NCT00002342Phase 1Completed

A Study of Tecogalan Sodium

Role: lead

NCT00002137Phase 1Completed

A Phase I Trial of Tecogalan Sodium ( DS-4152 ) Administered as an Infusion Weekly x 4

Role: lead

All 8 trials loaded